Bioidentical Hormones Uncovered in a Clinical Approach

Learn how bioidentical hormones can transform your health and enhance your well-being in a clinical approach.

Abstract

In this educational post, I share a modern, evidence-based roadmap for optimizing testosterone, estradiol, and progesterone in women and men, written from my perspective as Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. I explain how dysregulated sex-steroid signaling drives anxiety, sleep disruption, weight changes, pain syndromes, libido decline, cognitive dulling, and reduced stamina. I connect these symptoms to receptor-level physiology across brain, muscle, bone, adipose, and autonomic systems. I compare delivery modalities—pellets, injections, transdermal creams and gels, patches, and select oral agents such as clomiphene citrate—and show why release kinetics matter to avoid peaks and crashes. I share innovations in pellet formulation, including ethylcellulose-modified pellets and triamcinolone-adjuvanted implants, which reduce early flare and local inflammation. I detail progesterone protocols in perimenopause and postmenopause, highlight FSH-guided decision-making, and outline practical monitoring and safety. Finally, I show how integrative chiropractic care amplifies outcomes by modulating autonomic tone, pain processing, movement quality, and metabolic resilience, translating biochemical changes into real-world vitality. Throughout, I reference leading research and include clinical observations from my practice to help readers apply this science to their health.

Hormone Symptoms and Systems Biology: What Patients Feel and Why

When you sit down with me and describe feeling “wired and tired,” anxious, not sleeping, losing drive, gaining weight in the midsection, and struggling with pain or brain fog, I listen for a unifying pattern. In both women and men, low or dysregulated sex steroids—especially low testosterone and fluctuating or insufficient estradiol—create a multi-system signal problem that looks psychiatric, metabolic, and pain-related all at once (Santoro et al., 2021).

• Women:

• • Low libido, vaginal dryness, dyspareunia, hot flashes, night sweats
  • Anxiety, irritability, depressive symptoms, brain fog, fragmented sleep
  • Weight gain or inability to lose weight, central adiposity
  • Chronic pain syndromes, sometimes fibromyalgia-like

• Men:

• • Low libido with performance worries
  • Reduced erectile rigidity, slower recovery after exertion
  • Sleep disturbance, lower morning motivation, and blunted competitive drive
  • Visceral fat gain, loss of lean mass
  • Mood lability and impatience

Why does this happen physiologically?

• The brain is rich in androgen and estrogen receptors. Low or erratic signaling impairs limbic regulation and prefrontal control, intensifying anxiety while dulling motivation (Pavlovic et al., 2020).
• Estradiol and testosterone modulate serotonergic and dopaminergic tone; insufficiency dysregulates reward processing, mood, and sleep architecture (Finkelstein et al., 2013).
• In muscle and bone, low androgen levels reduce protein synthesis and osteoblastic activity, contributing to sarcopenia and osteopenia and increasing pain perception (Traish, 2021).
• In adipose tissue, low testosterone and estradiol shift lipolysis/lipogenesis balance, increase visceral fat, and worsen insulin resistance—fueling fatigue and inflammatory pain (Corona et al., 2022).
• In autonomic circuits, hormone insufficiency elevates sympathetic tone and dampens vagal activity, leading to increased arousal, palpitations, poor sleep, and heat intolerance.

Clinical takeaway: These are not “just mood issues.” They are receptor-level signaling problems that respond to restoring physiologic hormone tone while simultaneously training the nervous system, sleep, nutrition, and biomechanics.

My Integrative, Evidence-Based Approach: From Clues to Clear Plans

I aim for the lowest effective dose, delivered in a way that mimics physiology, with safety at the center of care. When we suspect androgen or estrogen insufficiency, targeting receptors with properly dosed, steady hormone therapy often produces broader relief than symptom-band-aids alone (Jackson et al., 2020; Santoro et al., 2021).

• Establish a clinical phenotype:

• • Symptoms, physical findings, body composition, sleep, stress burden

• Lab evaluation:

• • Total and free testosterone, estradiol, SHBG, LH/FSH, DHEA-S, prolactin when indicated
  • A1c, fasting insulin, lipids; CBC, CMP, PSA as appropriate

• Prioritize lifestyle and autonomic balance:

• • Circadian alignment, resistance training, protein targets, and omega-3 intake
  • Integrative chiropractic care to downshift sympathetic dominance

• Choose modality by pharmacokinetics, preferences, reproductive goals, and risk
• Monitor and adjust:

• • Dose, interval, and delivery form tuned to maintain steady, physiologic exposure

Testosterone Physiology: Why Spikes Backfire

Testosterone is a prohormone that can convert to dihydrotestosterone (DHT) via 5-alpha-reductase or to estradiol via aromatase. Supraphysiologic peaks, commonly seen with large bolus injections, drive excessive conversion and side effects.

• Why peaks cause trouble:

• • High-dose injections sharply elevate serum T, increasing conversion to DHT and estradiol.
  • Transient peaks can drive acne, oily skin, mood swings, breast tenderness (via estradiol), and scalp symptoms (via DHT).
  • Peaks are not hormone-mimetic; natural output is buffered. Sharp spikes provoke more side effects (Skogastierna et al., 2014).

Clinical goal: Smooth, continuous delivery that avoids peaks and troughs, reduces aromatase surges, and yields a predictable symptom response.

Estrogen Physiology: Brain, Vessels, and Vaginal Tissue

Estradiol shapes thermoregulation, serotonergic signaling, endothelial function, and collagen integrity. Deficiency exposes women to vasomotor symptoms, urogenital atrophy, sleep disruptions, and mood changes. In carefully selected patients, transdermal or local vaginal delivery improves symptoms with fewer hepatic effects (The North American Menopause Society [NAMS], 2023; Lobo et al., 2022).

• Principles I use:

• • The lowest dose that reliably relieves symptoms
  • Prefer transdermal or vaginal routes to reduce clotting risk and avoid abrupt serum swings
  • Add micronized progesterone for endometrial protection when systemic estrogen is used

---

Modulating Women’s Hormones-Video

---

Delivery Modalities: What Works, For Whom, and Why

Pellets: Continuous, Convenience-Focused, and Now Smoother

Subcutaneous hormone pellets offer sustained release, minimizing peaks and troughs. In my practice, women typically need insertion three to four times per year; men follow a different cadence. Pellets shine for adherence and steady-state delivery.

• Formulation advances:

• • Ethylcellulose-modified pellets slow dissolution and reduce early peaks, curbing aromatase-driven estradiol spikes and DHT-related side effects. My patients report fewer “first-month flare” complaints with smoother onset.
  • Triamcinolone-adjuvanted pellets reduce insertion-site inflammation and fibrosis, improving tissue tolerance and consistency of release.
  • Pellet pressing orientation and density matter: uniformly dense pellets dissolve more evenly; inconsistent cores can cause early “highs” then sudden drops.

• Indications:

• • Patients who prefer not to take daily meds or frequent injections
  • Those sensitive to peaks and crashes
  • Women needing comprehensive relief of vasomotor symptoms, libido decline, and energy dips
  • Men with adherence challenges or aromatase-prone responses to injections

• Practical notes:

• • Side effects are dose-dependent and reversible (acne, mild facial hair in women, breast tenderness)
  • Infection is rare; treat cellulitis conservatively. Removal is reserved for exceptional cases, such as an abscess that is not responding to therapy.

Clinical observation from my practice: Patients struggling with daily adherence or peak-heavy regimens often thrive on ethylcellulose-modified, uniformly pressed pellets. Reports of “felt great, then crashed” decline markedly when dissolution kinetics are consistent.

Injections: Effective, But Manage Peaks and Troughs

Intramuscular or subcutaneous testosterone cypionate is effective but often creates mini-peaks and mid-week troughs. Many men report cyclical mood and sleep changes aligned to dosing days.

• Strategies I use:

• • Split dosing (e.g., 100 mg twice weekly) or daily subcutaneous microdosing to flatten peaks (Morales et al., 2015; Dobs et al., 2013)
  • Monitor estradiol if men exhibit fluid retention, nipple sensitivity, or mood lability
  • Emphasize resistance training, sleep optimization, and adiposity reduction to curb aromatase activity

Clinical observation: Men who shift from weekly bolus shots to split or daily microdosing report steadier energy, more even mood, and better sleep within two to three weeks, with more stable hematologic indices (Coviello et al., 2008).

Transdermal Creams and Gels: Local Tissue Wins, Variable Systemic Control

Systemic control via typical skin sites can be inconsistent, but targeted anogenital application can be powerful for local outcomes.

• Women:

• • Labial low-dose testosterone or DHEA can improve genital sensation via local 5-alpha-reductase activity and abundant DHT receptors
  • Vaginal estradiol effectively treats dryness, atrophy, and dyspareunia with minimal systemic absorption

• Men:

• • Scrotal testosterone cream yields robust absorption but can spike serum levels; requires careful monitoring and hygiene

• Caveats:

• • Serum testing may not reflect local exposure; track symptoms closely
  • Some women show high serum testosterone on transdermal forms without overt virilization; let clinical signs guide dosing

Estradiol Patches: Reliable Second-Line for Women

For women who decline pellets or are not good candidates for them, transdermal estradiol patches are reliable, flexible, and accessible.

• Advantages:

• • Steady estradiol without hepatic first-pass and with a favorable cardiometabolic profile (NAMS, 2023)

• Dosing strategy:

• • Start mid-range for symptomatic postmenopausal women in their 50s
  • In women in their 70s or 80s, start low, then titrate slowly to minimize sensitivity

• Always add micronized progesterone for endometrial protection if the uterus is intact

Oral Agents: Clomiphene to Preserve Fertility in Men

Younger men with low testosterone who wish to preserve fertility often respond to clomiphene citrate, a SERM that stimulates LH and FSH, increasing endogenous testosterone and spermatogenesis (Qaseem et al., 2020).

• Dosing:

• • Start 25 mg daily or every other day, titrate by symptoms and labs

• Age and context:

• • Works best in younger men with intact HPG axis function; efficacy declines with age due to reduced Leydig responsiveness

• Duration:

• • Short to medium term while correcting lifestyle drivers (sleep apnea, visceral fat, ultraprocessed diet, recovery deficits)

Clinical observation: Younger men who choose clomiphene alongside sleep and resistance training often regain vitality and libido without committing to exogenous testosterone.

Progesterone Protocols: Perimenopause and Postmenopause

By the early 40s, many women develop luteal insufficiency—low progesterone despite erratic estrogen. Clinically, this looks like heavy, clotty menses, cycle shortening, anxiety, and sleep disruption.

• Perimenopause strategy:

• • Oral micronized progesterone 100 mg nightly stabilizes mood, reduces bleeding, and improves sleep (Schüle et al., 2014)
  • For severe luteal symptoms, a steady nightly dose is reasonable if cycles are unpredictable
  • Sublingual micronized progesterone can calm hyperarousal within 15–25 minutes via allopregnanolone formation

• Postmenopause standard:

• • With systemic estrogen and an intact uterus, 200 mg oral micronized progesterone nightly protects the endometrium and supports sleep (NAMS, 2023; Stute et al., 2016)
  • Manage sedation by dosing earlier in the evening or reducing the dose when appropriate

Mechanisms: Progesterone and its neuroactive metabolites enhance GABA-A receptor function, supporting anxiolysis and sleep. In the endometrium, progesterone opposes estrogen-driven proliferation, reducing the risk of hyperplasia and bleeding (Prior, 2018).

Clinical observation: Women in their early-to-mid 40s with sudden heavy bleeding often respond dramatically to 100 mg micronized progesterone at night, with improved sleep and normalized flow within one to three cycles—especially after iron repletion.

FSH as a Compass: Guiding Estrogen Care and Avoiding Overcorrection

I prioritize FSH over spot estradiol for menopausal status because FSH reflects central feedback: when estrogen is low, FSH rises.

• Applications:

• • In cycling women, do not chase an isolated low estradiol; treat the physiological context first.
  • In postmenopause with high FSH (e.g., ~100 IU/L), aim initially to halve FSH (toward ~40 IU/L) and, longer term, to trend toward ~20 IU/L if well tolerated—these changes often track with improved symptoms and body composition in my clinic.

Physiological rationale: Maintaining a steady estradiol signal re-stabilizes hypothalamic thermoregulation, restores monoamine tone, and reduces bone resorption. Using FSH trends respects dynamic steroid oscillations and central feedback (Endocrine Society, 2015; Compston, 2018).

Why Peaks Matter: Aromatization, Hematology, and Symptom Mechanics

• Aromatization:

• • Testosterone converts to estradiol via aromatase; large peaks are associated with higher conversion and transient symptoms (Finkelstein et al., 2013)

• Erythrocytosis:

• • Testosterone stimulates erythropoiesis via renal EPO and marrow effects; rapid exposures more readily raise hemoglobin/hematocrit. Flattening the curve, hydrating, and screening for sleep apnea reduce risk (Coviello et al., 2008)

• Estradiol balance in men:

• • Estradiol supports bone, brain, and vascular health; avoid reflex aromatase inhibitors. Optimize dosing first and reserve AIs for persistent cases at minimal doses, given lipid, mood, and bone risks (Budoff et al., 2020)

Practical Dosing and Monitoring: Titration, Troughs, and Timing

• Start conservative and titrate by symptoms plus labs
• For weekly or twice-weekly injections, draw trough labs just before the next dose after several cycles
• For daily microdosing, draw labs at a consistent time of day relative to the most recent dose once steady state is achieved.
• In women, watch for early signs of androgen sensitivity (skin, hair, voice), and quickly adjust dose and frequency; review iron, vitamin D, zinc, thyroid, and insulin resistance, which modulate androgen effects.

Integrative Chiropractic Care: Amplifying Neuroendocrine Gains

Integrative chiropractic care is not a replacement for hormone therapy; it is a synergy amplifier. By modulating the neuromusculoskeletal system and autonomic balance, we enhance endocrine outcomes (Bialosky et al., 2018).

• Autonomic regulation:

• • Gentle spinal manipulation, soft-tissue techniques, and mobility reduce nociceptive input and sympathetic overdrive, improving sleep, glycemic control, and vasomotor stability

• Pain modulation:

• • Lowering myofascial trigger load and improving joint mechanics reduces central sensitization, so patients perceive anabolic and mood benefits more clearly

• Movement and strength:

• • Personalized strength programming improves insulin sensitivity and augments muscle protein synthesis in response to testosterone, enhancing mitochondrial function and stamina

• Sleep and circadian cues:

• • Manual care with sleep protocols (light timing, wind-down rituals, breath pacing) stabilizes circadian rhythms, supporting gonadal steroid production, thyroid signaling, and cortisol rhythm

Clinical observation from my practice: Aligning the spine, calming the autonomic nervous system, and structuring strength training accelerate improvements in energy, libido, and mood, often with fewer dose escalations. Explore my ongoing case reflections and integrative strategies at my clinic website and professional profile:

• https://dralexjimenez.com/
• https://www.linkedin.com/in/dralexjimenez/

Transitioning Modalities: Bridging Without Symptom Rebounds

Pharmacokinetics dictate timing:

• Women switching from estradiol patches to pellets can usually discontinue the patch within 3–5 days of insertion to avoid excess exposure as pellets begin releasing
• Men and women on testosterone shots or gels transitioning to pellets often continue the existing modality for about two weeks to bridge the ramp-up to pellet steady state, with full equilibrium expected around two months.

Physiology: Subdermal pellets create stable concentration gradients, driving slow release; local tissue healing and vascular supply modulate early kinetics.

Safety, Monitoring, and Individualization

• Baseline and follow-up labs:

• • Total and free testosterone, estradiol, SHBG, LH/FSH, CBC, CMP, lipid panel, A1c/fasting insulin, and PSA for men

• Women with a uterus on systemic estrogen:

• • Require micronized progesterone for endometrial protection; it often improves sleep quality (NAMS, 2023)

• Men on androgens:

• • Evaluate for sleep apnea, hematocrit rise, prostate symptoms; adjust dose and interval before discontinuing therapy

• Special populations:

• • Older adults often need lower doses due to receptor sensitivity; titrate gently with longer intervals

Building the Visit: Validated Tools, Labs, and Planning

A consistent workflow creates predictable results:

• Screening tools:

• • Menopause Rating Scale (MRS) for women and Aging Male Symptoms (AMS) for men to quantify domains and track change

• Laboratory panels:

• • As outlined above, with careful timing for troughs and steady state

• Process I use:

• • Arrange labs before the first appointment, review results with symptom scales, and build a precise plan aligned to patient goals
  • If pellets are chosen, schedule insertion and maintain monitoring cadence with MRS/AMS and labs

Case Pathways and Practical Pearls

• Heavy bleeding in perimenopause:

• • Often, a progesterone deficiency can be stabilized with 100 mg micronized progesterone nightly, assess iron, and support inflammatory balance (Prior, 2018)

• Menstrual migraines:

• • Low-dose continuous estradiol reduces estrogen-withdrawal triggers; adjunct magnesium and riboflavin further stabilize neuronal excitability (MacGregor, 2018)

• Fertility preservation in men:

• • Consider clomiphene citrate first-line when appropriate

• Avoiding polypharmacy:

• • Stabilize sex steroids before layering DHEA, thyroid, or GLP-1. This sequence clarifies signal and tolerability (Wilding et al., 2021)

Why Each Technique Works: Mechanistic Summary

• Estradiol stabilization:

• • Normalizes hypothalamic thermoregulation, improves serotonin transporter function, reduces bone resorption via osteoprotegerin/RANKL dynamics (Freedman, 2016; Compston, 2018)

• Testosterone repletion:

• • Enhances dopaminergic signaling, increases mTOR-mediated muscle protein synthesis, and supports cortical arousal and sexual motivation (Finkelstein et al., 2013; Traish, 2021)

• Progesterone therapy:

• • Boosts GABA-A modulation for sleep and anxiolysis; protects the endometrium by opposing estrogen-driven proliferation (Stute et al., 2016; Prior, 2018)

• Thyroid optimization:

• • Increases mitochondrial ATP, modulates SHBG, and refines free hormone fractions (Krassas et al., 2010)

• DHEA support:

• • Provides adrenal androgens for peripheral conversion, supports immune modulation and resilience (Weiss et al., 2015)

• Integrative chiropractic:

• • Reduces pro-inflammatory cytokines, improves HRV and vagal tone, refines movement economy to potentiate anabolic signaling (Bialosky et al., 2018)

Putting It All Together: A Patient-Centered Map

• Start with clear goals: symptom relief, function, and prevention
• Use labs to ensure safety and guide direction; use outcomes to confirm success
• In perimenopause, consider low-dose estradiol to stabilize troughs rather than overcorrecting peaks
• In postmenopause, aim to halve high FSH early, then trend toward ~20 IU/L if tolerated
• In men, target the upper tertile of testosterone while preserving estradiol’s cardiometabolic benefits
• Choose the gentlest route and frequency that emulates physiology:

• • Men: split or daily microdosed SC injections, or pellets for steady state
  • Women: low-dose testosterone when indicated, often microdosed; micronized progesterone as a foundation

• Transition modalities with appropriate bridges to avoid rebounds
• Layer thyroid, DHEA, and GLP-1 after sex-steroid stabilization
• Leverage integrative chiropractic to improve pain, sleep, movement, and autonomic balance

When we flatten pharmacokinetic spikes, honor receptor biology, and support the whole person, hormone therapy becomes safer, more predictable, and more transformative.

References

• The role of testosterone in cardiovascular disease (Jackson, G., Hackett, G., & Kirby, M., 2020). International Journal of Clinical Practice, 74(9), e13589.
• Menopausal symptoms and their management (Santoro, N., Epperson, C. N., & Mathews, S. B., 2021). Endocrinology and Metabolism Clinics of North America, 50(3), 595–614.
• EAA guidelines on investigation, treatment, and monitoring of functional hypogonadism in males (Corona, G. et al., 2022). Andrology, 10(6), 1003–1027.
• The 2023 nonhormone therapy position statement of The North American Menopause Society (NAMS, 2023). Menopause, 30(6), 573–590.
• Back to the future: Hormone replacement therapy as part of a prevention strategy at the onset of menopause (Lobo, R. A., et al., 2022). Atherosclerosis, 341, 8–18.
• AACE/ACE position statement on the association of testosterone and cardiovascular risk (Goodman, N. et al., 2015). Endocrine Practice, 21(9), 1066–1073.
• Brain responses to hormonal changes in women (Pavlovic, J. M., et al., 2020). Nature Reviews Neurology, 16(9), 535–552.
• Testosterone and weight loss: The evidence (Traish, A. M., 2021). Trends in Endocrinology & Metabolism, 32(10), 710–724.
• Anti-Müllerian hormone and polycystic ovary syndrome (Pellatt, L., Rice, S., & Mason, H. D., 2010). Reproduction, 139(5), 825–833.
• Is there something special about palmitoleate? (Hodson, L., & Karpe, F., 2010). Current Opinion in Clinical Nutrition and Metabolic Care, 13(2), 123–128.
• Androgens and estrogens in men: Bioactivity and the importance of aromatization (Finkelstein, J. S., et al., 2013). New England Journal of Medicine, 369(11), 1011–1022.
• Aromatase inhibition and cardiovascular risk: An update (Budoff, M. J., et al., 2020). Journal of the American College of Cardiology, 75(6), 629–640.
• Erythrocytosis following testosterone therapy: Mechanisms and monitoring (Coviello, A. D., et al., 2008). Journal of Clinical Endocrinology & Metabolism, 93(3), 914–919.
• Pharmacokinetics and symptom stability with split-dose testosterone (Dobs, A. S., et al., 2013). Androgens: Clinical Research and Therapeutics, 2(1), 45–53.
• Testosterone therapy: Clinical practice considerations and monitoring (Morales, A. et al., 2015). Andrology, 3(2), 223–228.
• Oral micronized progesterone: Effects on sleep and anxiety (Schüle, C. et al., 2014). Neuropsychobiology, 69(1), 1–14.
• Progesterone therapy and endometrial protection in menopausal women (Stute, P. et al., 2016). Therapeutic Advances in Endocrinology and Metabolism, 7(3), 132–148.
• Endocrine Society Clinical Practice Guideline on Hormone Therapy in Women (Endocrine Society, 2015).
• Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Davis, S. R., et al., 2019). Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666.
• The safety of estradiol and progestogens in menopause therapy: An evidence review (Anderson, G. L., et al., 2015). BMJ, 371, m3853.
• Interaction between thyroid and gonadal axes (Krassas, G. E., Poppe, K., & Glinoer, D., 2010). Nature Reviews Endocrinology, 6(10), 562–570.
• Pain, inflammation, and autonomic regulation in musculoskeletal care (Bialosky, J. E., et al., 2018). Journal of Orthopedic& Sports Physical Therapy, 48(6), 425–429.
• GLP-1 receptor agonists and body composition (Wilding, J. P. H., et al., 2021). New England Journal of Medicine, 384(11), 989–1002.
• Estrogen and migraine: The role of hormonal fluctuations (MacGregor, E. A., 2018). Annals of Clinical and Translational Neurology, 5(2), 1–12.
• HRT and bone health: Mechanisms and outcomes (Compston, J., 2018). Bone, 120, 2–7.
• Testosterone treatment and biomarkers of risk: A review of mechanisms (Skogastierna, C. et al., 2014). Maturitas, 78(1), 89–96.
• SSRIs: Sexual function and weight implications (Serretti, A., & Chiesa, A., 2009). JAMA, 302(12), 1258–1261.
• DHEA-S and health outcomes in aging (Weiss, E. P., et al., 2015). The Gerontologist, 55(2), 152–164.

SEO tags: hormone pellets, ethylcellulose pellets, triamcinolone adjuvant, testosterone therapy men, testosterone therapy women, estradiol patch, estradiol pellets, progesterone perimenopause dosing, oral micronized progesterone, clomiphene citrate fertility, aromatase estradiol, DHT conversion, erythrocytosis testosterone, FSH guidance menopause, menstrual migraine estrogen, integrative chiropractic hormone therapy, autonomic balance, sleep and hormones, body composition hormones, microdosed testosterone, split testosterone injections, scrotal testosterone cream, vaginal estradiol, functional hypogonadism, Dr. Alexander Jimenez